Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flu BHPV E6E7

Next Previous
Drug Profile

Flu BHPV E6E7

Alternative Names: delNS/E6E7; delNS106; delNS106/E6E7; Flu-BHPV-E6E7

Latest Information Update: 25 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BlueSky Immunotherapies
  • Class Antineoplastics; Cancer vaccines; COVID-19 vaccines; Immunotherapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia; Human papillomavirus infections; Squamous cell cancer
  • No development reported COVID 2019 infections

Most Recent Events

  • 25 Jun 2026 Flu BHPV E6E7 is still in phase I trials for Cervical-intraepithelial-neoplasia in Austria (BlueSky Immunotherapies pipeline, June 2026)
  • 25 Jun 2026 Phase-I clinical trials in Squamous cell cancer (Neoadjuvant therapy) (Parenteral) before June 2026 (BlueSky Immunotherapies pipeline, June 2026)
  • 28 Jun 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Austria (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top